Dragonfly Therapeutics has a total of 683 patents globally, out of which 20 have been granted. Of these 683 patents, more than 87% patents are active. The United States of America and Japan is where Dragonfly Therapeutics has filed the maximum number of patents, followed by Singapore and Europe. Parallely, United States of America seems to be the main focused R&D centre and also is the origin country of Dragonfly Therapeutics.
Dragonfly Therapeutics was founded in 2016. Dragonfly Therapeutics is a clinical-stage biopharmaceutical business dedicated to discovering, developing, and commercializing therapeutics that harness the body’s immune system to provide patients innovative treatments. It has also successfully collaborated with Merck, AbbVie, Gilead and Bristol Myers Squibb across a wide range of disease categories.
Do read about some of the most popular patents of Dragonfly Therapeutics which have been covered by us in this article and also you can find Dragonfly Therapeutics patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Dragonfly Therapeutics patent portfolio.
How many patents does Dragonfly Therapeutics have?
Dragonfly Therapeutics has a total of 683 patents globally. These patents belong to 73 unique patent families. Out of 683 patents, 598 patents are active.
How Many Patents did Dragonfly Therapeutics File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | Dragonfly Therapeutics Applications Filed | Dragonfly Therapeutics Patents Granted |
| 2023 | 21 | 17 |
| 2022 | 52 | 1 |
| 2021 | 104 | 1 |
| 2020 | 106 | – |
| 2019 | 193 | 1 |
| 2018 | 206 | – |
How many Dragonfly Therapeutics patents are Alive/Dead?
Worldwide Patents
How Many Patents did Dragonfly Therapeutics File in Different Countries?
Countries in which Dragonfly Therapeutics Filed Patents
| Country | Patent |
| Japan | 49 |
| United States Of America | 49 |
| Singapore | 45 |
| Europe | 43 |
| Canada | 41 |
| China | 40 |
| Korea (South) | 39 |
| Israel | 38 |
| Australia | 38 |
| Mexico | 37 |
| India | 36 |
| Brazil | 34 |
| South Africa | 34 |
| Hong Kong (S.A.R.) | 30 |
| Taiwan | 11 |
| Chile | 11 |
| Malaysia | 11 |
| Saudi Arabia | 10 |
| Peru | 10 |
| Colombia | 8 |
| New Zealand | 8 |
| Argentina | 5 |
| Eurasia | 4 |
| Russia | 3 |
| Italy | 2 |
| Finland | 2 |
| Denmark | 2 |
| Norway | 2 |
| Pakistan | 1 |
| Austria | 1 |
Where are Research Centers of Dragonfly Therapeutics Patents Located?
10 Best Dragonfly Therapeutics Patents
CN110662555A is the most popular patent in the Dragonfly Therapeutics portfolio. It has received 10 citations so far from companies like Shanghai Luoqi Biomedical Technology, Innovent Biologics (Suzhou) and Gigagen.
Below is the list of 10 most cited patents of Dragonfly Therapeutics:
| Publication Number | Citation Count |
| CN110662555A | 10 |
| WO2018217799A1 | 9 |
| WO2020033702A1 | 8 |
| WO2019231920A1 | 8 |
| WO2019195409A1 | 7 |
| WO2019157332A1 | 7 |
| US20200376034A1 | 6 |
| WO2019051308A1 | 5 |
| WO2018157147A1 | 5 |
| CN111315778A | 4 |
What Percentage of Dragonfly Therapeutics US Patent Applications Were Granted?
Dragonfly Therapeutics (Excluding its subsidiaries) has filed 29 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 0 have been granted leading to a grant rate of 0%.
Below are the key stats of Dragonfly Therapeutics patent prosecution at the USPTO.
Which Law Firms Filed Most US Patents for Blue Oak Pharmaceuticals?
| Law Firm | Total Applications | Success Rate |
| Goodwin Procter Llp | 23 | 0% |
List of Dragonfly Therapeutics Patents
| Dragonfly Therapeutics Patents | Title |
| US20230109801A1 | Compounds And Compositions For Treating Cns Disorders |
| US20230116114A1 | Compounds And Compositions For Treating Cns Disorders |
| EP4084795A1 | Compounds And Compositions For Treating Cns Disorders |
| EP4084797A1 | Compounds And Compositions For Treating Cns Disorders |
| CN114929235A | Compounds And Compositions For Treating Cns Disorders |
| CN114929228A | Compounds And Compositions For Treating Cns Disorders |
| CA3161867A1 | Compounds And Compositions For Treating Cns Disorders |
| CA3165217A1 | Compounds And Compositions For Treating Cns Disorders |
| AU2020417248A1 | Compounds And Compositions For Treating Cns Disorders |
| AU2020416203A1 | Compounds And Compositions For Treating Cns Disorders |
| JP2023509700A | Compounds And Compositions For Treating Cns Disorders |
| JP2023509453A | Compounds And Compositions For Treating Cns Failure |
| HK40082254A | Compounds And Compositions For Treating Cns Disorders |
| HK40082232A | Compounds And Compositions For Treating Cns Disorders |
| IN202217034823A | Compounds And Compositions For Treating Cns Disorders |
| IN202217032225A | Compounds And Compositions For Treating Cns Disorders |
| KR1020220123404A | Compounds And Compositions For Treating Cns Disorders |
| KR1020220123406A | Compounds And Compositions For Treating Cns Disorders |
| BR112022010021A2 | Compounds And Compositions For Treatment Of Central Nervous System (Cns) Disorders |
| BR112022010641A2 | Compounds And Compositions For Treatment Of Central Nervous System (Cns) Disorders |
| WO2022204150A1 | Compounds And Compositions For Treating Cns Disorders |
| WO2021138314A1 | Compounds And Compositions For Treating Cns Disorders |
| WO2021138315A1 | Compounds And Compositions For Treating Cns Disorders |
What are Dragonfly Therapeutics key innovation segments?
What Technologies are Covered by Dragonfly Therapeutics?
The chart below distributes patents filed by Dragonfly Therapeutics